Showing 742 results
-
Press release /Tafinlar + Mekinist is the first oral targeted adjuvant combination therapy to demonstrate significant clinical benefit in patients with a BRAF V600 mutation, following complete surgical resection…
-
Press release /European Commission approves Sandoz Rixathon® to treat blood cancers and immunological diseases. Approval expected to broaden patient access to biologics and enable budget-constrained healthcare…
-
Press release /Chiffre d'affaires net en hausse de 2% (tcc[1], +2% USD), avec une croissance dans toutes les divisions: Cosentyx (USD 556 millions, +83% tcc) a affiché une forte hausse dans toutes ses…
-
Ad hoc release /Phase III PREVENT study met 16-week primary endpoint of ASAS40 in patients with active non-radiographic axial spondyloarthritis (nr-axSpA). All secondary endpoints were also met [1] Novartis has…
-
Press release /EC approves Xolair® (omalizumab) as an add-on therapy for severe chronic rhinosinusitis with nasal polyps, the first anti-immunoglobulin E antibody approved in this indication1 Chronic…
-
Press release /New Cosentyx® (secukinumab) label to include 300 mg up-titration option is informed by results from the Phase III MEASURE 3 study[1] Approval provides clinicians with greater choice for their…
-
Press release /Sandoz completes acquisition of worldwide brand rights for Mycamine® (micafungin sodium) from Astellas Leading global echinocandin, one of three major antifungal classes, will significantly…
-
Press release /Sales, core[1] operating income and core EPS grew (cc[1]) for continuing operations[2] in Q2: Net sales amounted to USD 12.7 billion (-5%, +6% cc) Operating income was USD 2.3…
-
Press release /New Cosentyx® (secukinumab) label to include dosing flexibility up to 300 mg, based on clinical response, and 24-week structural data with subcutaneous (sc) regimens[1] Cosentyx inhibits…
-
Ad hoc release /Novartis to focus Sandoz division in US on higher growth areas and will sell selected portions of the Sandoz US portfolio to Aurobindo Pharma USA Inc. Agreement comprises the Sandoz US generic…